Form 8-K - Current report:
SEC Accession No. 0001628280-24-012261
Filing Date
2024-03-20
Accepted
2024-03-20 17:20:34
Documents
19
Period of Report
2024-03-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20240320.htm   iXBRL 8-K 37990
2 EX-1.1 exhibit11salesagreement.htm EX-1.1 298943
3 EX-5.1 exhibit51opinion.htm EX-5.1 19072
7 image_01a.jpg GRAPHIC 278098
8 image_0a.jpg GRAPHIC 110
9 image_2a.jpg GRAPHIC 110
10 image_4a.jpg GRAPHIC 110
  Complete submission text file 0001628280-24-012261.txt   929830

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20240320.xsd EX-101.SCH 2013
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20240320_lab.xml EX-101.LAB 21885
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20240320_pre.xml EX-101.PRE 12611
22 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20240320_htm.xml XML 2828
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 24768641
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)